ResearcherNebraska Medical CenterActive in the last 2 years
Caitlin Molczyk
Matched on ORCID iD 0000-0001-6397-1099; OpenAlex author ID A5084827083. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 1 paper
Papers 5
- Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1096/fba.2025-00265↗
- Neutrophil Dynamics Contribute to Disease Progression and Poor Survival in Pancreatic Cancer. Co-author DOI 10.3390/cancers17213541↗
- The CXCR1 as a putative marker for cancer stem cell-like phenotypes in chemotherapy-resistant pancreatic ductal adenocarcinoma. Co-author DOI 10.62347/ylhf5834↗
- Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer. First author DOI 10.1016/j.canlet.2023.216185↗
- Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinoma. First author PMID 35141005↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Reegan Sturgeon · 3 shared papers, 2023–2026 · strength 0.77
- Paper Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1096/fba.2025-00265↗
- Paper Neutrophil Dynamics Contribute to Disease Progression and Poor Survival in Pancreatic Cancer. DOI 10.3390/cancers17213541↗
- Paper Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer. DOI 10.1016/j.canlet.2023.216185↗
- Rakesh K. Singh · 3 shared papers, 2023–2026 · strength 0.77
- Paper Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1096/fba.2025-00265↗
- Paper Neutrophil Dynamics Contribute to Disease Progression and Poor Survival in Pancreatic Cancer. DOI 10.3390/cancers17213541↗
- Paper Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer. DOI 10.1016/j.canlet.2023.216185↗
- Sugandha Saxena · 3 shared papers, 2022–2026 · strength 0.63
- Paper Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1096/fba.2025-00265↗
- Paper Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer. DOI 10.1016/j.canlet.2023.216185↗
- Paper Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinoma. PMID 35141005↗
- Surinder K. Batra · 3 shared papers, 2022–2026 · strength 0.63
- Paper Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1096/fba.2025-00265↗
- Paper Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer. DOI 10.1016/j.canlet.2023.216185↗
- Paper Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinoma. PMID 35141005↗
- Michael Anthony Hollingsworth · 2 shared papers, 2022–2025 · strength 0.42
- Paul M. Grandgenett · 2 shared papers, 2022–2025 · strength 0.42
- Abhilasha Purohit · 2 shared papers, 2022–2023 · strength 0.33
- Dipakkumar R. Prajapati · 2 shared papers, 2022–2023 · strength 0.33
- Namita Bhyravbhatla · 1 shared paper, 2026 · strength 0.30
- Rick Bhatia · 1 shared paper, 2026 · strength 0.30
- Sushil Kumar · 1 shared paper, 2026 · strength 0.30
- Sushil Kumar K · 1 shared paper, 2023 · strength 0.18
- Pranita Atri · 1 shared paper, 2022 · strength 0.14
- Rakesh K. Singh · 1 shared paper, 2022 · strength 0.14
- Sukhwinder Kaur · 1 shared paper, 2022 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.